X-ray price cuts hit Schering's diagnostics sales
This article was originally published in Clinica
Executive Summary
Price cuts in X-ray contrast media in Germany and Japan resulted in a 2% drop in Schering's diagnostics sales in 1997. In constant currencies, this reflects a 5% decline. However, Schering says sales of Magnevist, its top-selling magnetic resonance imaging (MRI) product, rose 10%, contrary to the general trend in this market. This is due in part to co-operation agreements with major purchasing organisations in the US. German company Schering says it has a leading position in the market for X-ray, MRI and ultrasound contrast media.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.